medigraphic.com
ISSN 1405-8871 (Print)

2023, Number 4

<< Back Next >>

Aten Fam 2023; 30 (4)

Frequency of Dyslipidemias and Cardiovascular Risk Determination in Patients with Systemic Arterial Hypertension

Sosa-Martínez MJ, León-Lozano IJ, García-Jiménez Y, Garduño-Orbe B, Lagarza-Moreno AJ, Juanico-Morales G

Language: Spanish
References: 30
Page: 245-250
PDF size: 137.71 Kb.


ABSTRACT

Objective: to determine the frequency of dyslipidemia and cardiovascular risk (CVR) in patients with systemic arterial hypertension (SAH) in a family medicine unit. Methods: analytical cross-sectional study conducted at the Family Medicine Unit No. 26 of the Mexican Institute of Social Security (IMSS) in Acapulco, Mexico, which included 150 patients with a confirmed diagnosis of systemic arterial hypertension in the electronic clinical record, obtained by non-probabilistic sampling by convenience, from November 2020 to May 2021. It was applied a questionnaire to obtain sociodemographic information, somatometry, laboratory tests, and the cardiovascular risk was assessed with the Globorisk estimation table. Descriptive statistics, bivariate and multivariate analysis were performed with the obtained data. Results: the frequency of dyslipidemia was 56.7% (n= 85), with a greater distribution in women 67% (n= 57), female to male ratio 2:1, 22.7% (n= 34) had mixed hyperlipidemia. 48% (72/150) presented moderate cardiovascular risk. Being a man and having a glomerular filtration rate ‹60 ml/min/1.27m2sc increased the possibility of presenting high cardiovascular risk. Conclusion: moderate cardiovascular risk was observed in almost half of the patients. Being male and having a gfr ‹60 ml/min/1.27m2sc increased the risk of presenting high CVR.


REFERENCES

  1. McDermott MM. The international pandemicof chronic cardiovascular disease. jama. 2007;297(11):1253-5.

  2. Organización Panamericana de la Salud. Prevenciónde las enfermedades cardiovasculares, directricespara la evaluación y el manejo del riesgo cardiovascular.Washington, D.C. ops, 2010. [Internet].[Citado 2021 Jun 20]. Disponible en: https://www.paho.org/hq/dmdocuments/2011/Directrices-paraevaluacion-y-manejo-del-riego-CV-de-OMS.pdf

  3. Jardim TV, Sousa AL, Povoa TI, Barroso WK, ChinemB, Jardim L, et al. The natural history of cardiovascularrisk factors in Health professionals: 20-yearfollow-up. BMC Public Health. 2015;15:1111.

  4. Hernández PYZ. Aterosclerosis y sistema aterométrico.Rev Cub Med Mil. 2016;45(2):183-194.

  5. Organización Mundial de la Salud. EnfermedadesCardiovasculares. Ginebra: centro de prensa oms;2017. [Internet]. [Citado 2022 abril 8]. Disponibleen: https://www.who.int/es/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

  6. Fanghanel SG, Velázquez MO, Lara EA, SánchezRL, Ledesma OY, Berber A, et al. Epidemiologíacardiovascular en México. Estudio comparativoentre datos nacionales y una población cautiva detrabajadores en el Distrito Federal. Diabet Hoy MedSal. 2004; 5(4): 1252-1261.

  7. Encuesta Nacional de Salud y Nutrición de mediocamino 2016. Instituto Nacional de Salud Pública ySecretaría de Salud. [Internet]. [Citado 2020 May15]. Disponible en: https://www.insp.mx/resources/images/stories/2017/Avisos/docs/180315_encuesta_nacional_de_salud_y_nutricion_de_medio_Ca.pdf

  8. Manton KG, Woodbury MA, Stallard E. Analysisof the components of chd risk in the Framinghamstudy: new multivariate procedures for the analysisof chronic disease development. Comput BiomedRes. 1979;12(2):109-23.

  9. Guía de Práctica Clínica. Diagnóstico y tratamientode hipertensión arterial en el adulto mayor. Guía deEvidencias y Recomendaciones: Guía de PrácticaClínica. México, imss; 2017. [Internet]. [Citado2020 Julio 2]. Disponible en: http://www.imss.gob.mx/sites/all/statics/guiasclinicas/238GER.pdf

  10. Factores de riesgo cardiovascular-Instituto del Corazónde Texas (Texas Heart Institute). Texasheart.org. 2016. [Internet]. [Citado 2021 Ene 5]. Disponibleen: https://www.texasheart.org/heart-health/heart-information-center/topics/factores-de-riesgocardiovascular/

  11. Secretaría de Salud. Programa Nacional de Salud2007-2012. [Internet]. [Citado 2021 Ene 7].Disponible en: https://www1.paho.org/hq/dmdocuments/2010/politicas_nacionales_salud-mexico_2007-2012.pdf

  12. Blood Pressure Lowering Treatment Trialists’ Collaboration.Blood pressure lowering treatment basedon cardiovascular risk: a meta-analysis of individualpatient data. Lancet. 2014;384(9943):591-598.

  13. National Cholesterol Education Program (ncep)Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol in Adults(Adult Treatment Panel III). Third Report of theNational Cholesterol Education Program (ncep)Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol in Adults(Adult Treatment Panel III) final report. Circulation.2002;106(25):3143-3421. Disponible en:https://pubmed.ncbi.nlm.nih.gov/12485966/

  14. Piepoli MF, Hoes AW, Agewall S, Albus C, BrotonsC, Catapano AL, et al. European Guidelines on cardiovasculardisease prevention in clinical practice:The Sixth Joint Task Force of the European Societyof Cardiology and Other Societies on CardiovascularDisease Prevention in Clinical Practice (constitutedby representatives of 10 societies and by invitedexperts): Developed with the special contributionof the European Association for CardiovascularPrevention & Rehabilitation (eacpr). Eur Heart J.2016;37(29):2315-2381.

  15. Andersson N, Mitchell S. CIETmap: Free GIS andepidemiology software from the cietgroup, helpingto build the community voice into planning. InWorld Congress of Epidemiology. Montreal, Canada,August 2002.

  16. Díaz AA, Fernández BCL, Enciso MJL, CeballosRG, Gutiérrez SG, León HFJ, et al. Posicionamientoen torno al diagnóstico y tratamiento de lasdislipidemias. Rev Mex Cardiol. 2018;29(Suppl:3):S148-S168.

  17. Ponte-Negretti CI, Isea-Pérez J, Lanas F, Medina J,Gómez-Mancebo J, Morales E, et al. Atherogenicdyslipidemia in Latin America: prevalence, causesand treatment. Consensus. Rev Mex Cardiol.2017;28(2):54-85.

  18. Rodríguez Rueda BY, Ramírez Bautista L, AlvaradoGutiérrez T, Cruz López M, Peralta Romero JJ. Prevalenciade dislipidemia y riesgo cardiovascular enpacientes con diabetes mellitus tipo 2. Aten Fam.2019;26(3):81-84.

  19. Vyssoulis GP, Karpanou EA, Liakos CI, KyvelouSM, Tzamou VE, Michaelides AP, et al. Cardiovascularrisk factor(s) prevalence in Greek hypertensives.Effect of gender and age. J Hum Hypertens.

  20. 2012;26(7):443-51.20. Escobedo-de la Peña J, De Jesús-Pérez R, SchargrodskyH, Champagne B. Prevalencia de dislipidemiasen la ciudad de México y su asociación con otrosfactores de riesgo cardiovascular. Resultados del estudiocarmela. Gac Med Mex. 2014;150(2):128-36.

  21. Gómez-Avellaneda G, Tarqui-Mamani C. Prevalenciade sobrepeso, obesidad y dislipidemia entrabajadores de salud del nivel primario. Duazary.2017;14(2):141-148.

  22. Orozco-González CN, Córtes-Sanabria L, Viera-Franco JJ, Ramírez-Márquez JJ, Cueto-ManzanoAM. Prevalencia de factores de riesgo cardiovascularen trabajadores de la salud. Rev Med Ins Mex SeguroSoc. 2016;54(5):594-601.

  23. Secretaría de Salud. Norma Oficial Mexicana nom-037-SSA2-2012, para la prevención, tratamiento ycontrol de las Dislipidemias. 13/07/2012. [Internet].[Citado 2020 May 8]. Disponible en: https://www.dof.gob.mx/nota_detalle.php?codigo=5259329&fecha=13/07/2012

  24. Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T, et al. Dyslipidemia prevalence, awareness,treatment and control in Mexico: results of theEnsanut 2012. Salud Publica Mex. 2020;62(2):137-146..

  25. García-González I, Novelo-Ceh A, López-NoveloME, Ceballos-López A, Góngora-Bianchi RA. Prevalenciade dislipidemias en población urbana aparentementesana de Yucatán. Rev Latinoam PatolClin Med Lab. 2015;62(3):150-156.

  26. Encuesta Nacional de Salud y Nutrición 2018.Instituto Nacional de Salud Pública y Secretaría deSalud. [Internet]. [Citado 2020 Agos 28]. Disponibleen: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_presentacion_resultados.pdf

  27. Catenacci VA, Hill JO, Wyatt HR. The obesity epidemic.Clin Chest Med. 2009;30(3):415-444.

  28. Wadhera RK, Steen DL, Khan I, Giugliano RP,Foody JM. A review of low-density lipoprotein cholesterol,treatment strategies, and its impact on cardiovasculardisease morbidity and mortality. J ClinLipidol. 2016;10(3):472-89.

  29. Zavala Rubio JD, Rivera Montellano ML, SánchezMartínez S, De la Mata Márquez MJ, Torres RodríguezMM. Prevalencia de factores y estratificaciónde riesgo cardiovascular en personal que laboraen una unidad de medicina familiar. Aten Fam.2019;26(4):129-133.

  30. Castelli WP, Anderson K. A population at risk.Prevalence of high cholesterol levels in hypertensivepatients in the Framingham study. Am J Med.1986;80:23-32.




2020     |     www.medigraphic.com